AC Immune reported positive interim Phase 1 first-in-human results for ACI-19764, an NLRP3 inhibitor aimed at reducing inflammation. While early-stage, the update is a favorable clinical development signal that could support investor confidence in the program’s feasibility.
AC Immune reported positive interim Phase 1 first-in-human results for ACI-19764, an NLRP3 inhibitor aimed at reducing inflammation. While early-stage, the update is a favorable clinical development signal that could support investor confidence in the program’s feasibility.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
